Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
American Journal of Clinical Dermatology

16.05.2024 | Review Article

Management and Long-Term Outcomes of Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS) in Children: A Scoping Review

verfasst von: Nicole Cherepacha, Frances St George-Hyslop, Bindiya Chugani, Yousef Alabdeen, Luis F. Sanchez-Espino, Quenby Mahood, Cathryn Sibbald, Ruud H. J. Verstegen

Erschienen in: American Journal of Clinical Dermatology

Einloggen, um Zugang zu erhalten

Abstract

Drug reaction with eosinophilia and systemic symptoms (DReSS) is known to cause mortality and long-term sequelae in the pediatric population, however there are no established clinical practice guidelines for the management of pediatric DReSS. We conducted a scoping review, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, to summarize the currently available data on treatment, mortality, and long-term sequelae of DReSS in children (aged 0–18 years). Data from 644 individuals revealed that various treatment strategies are being used in the management of pediatric DReSS, and strategies were often used in combination. The diversity in treatment approaches cannot be solely attributed to age or disease severity and reflects the lack of evidence-based management guidelines for DReSS. Children are also at risk of developing autoimmune sequelae following DReSS, most commonly thyroid disease and type 1 diabetes mellitus. We found that the eventual development of autoimmune disease was more often associated with DReSS caused by antibiotics, especially minocycline and sulfamethoxazole, in comparison with individuals who did not develop sequelae. In this study, we identify strengths and weaknesses in the currently available literature and highlight that future prospective studies with structured and long-term follow-up of children with DReSS are needed to better understand potential risk factors for mortality and development of sequelae after DReSS.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Kim GY, Anderson KR, Davis DMR, Hand JL, Tollefson MM. Drug reaction with eosinophilia and systemic symptoms (DRESS) in the pediatric population: a systematic review of the literature. J Am Acad Dermatol. 2020;83(5):1323–30.PubMedCrossRef
2.
Afiouni R, Zeinaty P, Kechichian E, Zoghaib S, Matar S, Helou-Mallat J, et al. Pediatric drug reaction with eosinophilia and systemic symptoms: a systematic review of the literature, with a focus on relapsing cases. Pediatr Dermatol. 2021;38(1):125–31.PubMedCrossRef
3.
Metterle L, Hatch L, Seminario-Vidal L. Pediatric drug reaction with eosinophilia and systemic symptoms: a systematic review of the literature. Pediatr Dermatol. 2020;37(1):124–9.PubMedCrossRef
4.
Stirton H, Shear NH, Dodiuk-Gad RP. Drug reaction with eosinophilia and systemic symptoms (DReSS)/drug-induced hypersensitivity syndrome (DiHS)-readdressing the DReSS. Biomedicines. 2022;10(5):999.
5.
Funck-Brentano E, Duong TA, Bouvresse S, Bagot M, Wolkenstein P, Roujeau JC, et al. Therapeutic management of DRESS: a retrospective study of 38 cases. J Am Acad Dermatol. 2015;72(2):246–52.PubMedCrossRef
6.
7.
Chen YC, Chang CY, Cho YT, Chiu HC, Chu CY. Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. J Am Acad Dermatol. 2013;68(3):459–65.PubMedCrossRef
8.
Ushigome Y, Kano Y, Ishida T, Hirahara K, Shiohara T. Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. J Am Acad Dermatol. 2013;68(5):721–8.PubMedCrossRef
9.
Deng M, Wu H, Yu M, Tian Y, Li Y, Xiao X. Co-occurrence of multiple endocrine abnormalities induced by the DIHS/DRESS. Int J Endocrinol. 2019;2019:7959615.PubMedPubMedCentralCrossRef
10.
Tempark T, Deekajorndech T, Chatproedprai S, Supornsilchai V, Wananukul S. Late sequelae of drug reaction with eosinophilia and systemic symptoms (DRESS) cause thyroid dysfunction and thyroiditis: review of literature. J Pediatr Endocrinol Metab. 2022;35(5):567–75.PubMedCrossRef
11.
Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–73.PubMedCrossRef
12.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.PubMedCrossRef
13.
Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071–80.PubMedCrossRef
14.
Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, et al. The DRESS syndrome: a literature review. Am J Med. 2011;124(7):588–97.PubMedCrossRef
15.
Awad A, Goh MS, Trubiano JA. Drug reaction with eosinophilia and systemic symptoms: a systematic review. J Allergy Clin Immunol Pract. 2023;11(6):1856–68.PubMedCrossRef
16.
St George-Hyslop F, Cherepacha N, Chugani B, Alabdeen Y, Sanchez-Espino LF, Mahood Q, et al. Clinical presentation and diagnosis of drug reaction with eosinophilia and systemic symptoms (DReSS) in children: a scoping review. Clin Rev Allergy Immunol. 2024;66(1):112–23.PubMedCrossRef
17.
Shah SV, Vora NS, Dave JN, Goel R, Chakraborty N, Bhagat S. Phenytoin hypersensitivity syndrome. Indian J Dermatol Venereol Leprol. 1997;63(1):68–9.PubMed
18.
Hicks RA, Murphy JV, Jackson MA. Kawasaki-like syndrome caused by carbamazepine. Pediatr Infect Dis J. 1988;7(7):525–6.PubMedCrossRef
19.
Santos RP, Ramilo O, Barton T. Nevirapine-associated rash with eosinophilia and systemic symptoms in a child with human immunodeficiency virus infection. Pediatr Infect Dis J. 2007;26(11):1053–6.PubMedCrossRef
20.
Yoo SD, Kim SG, Kim SH, Kim HY. Drug rash with eosinophilia and systemic symptoms syndrome induced by chloral hydrate in early childhood. Allergy Asthma Immunol Res. 2014;6(3):270–2.PubMedCrossRef
21.
Bedouelle E, Ben Said B, Tetart F, Milpied B, Welfringer-Morin A, Maruani A, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): series of 49 French pediatric cases. J Allergy Clin Immunol Pract. 2022;10(1):267-74.e5.PubMedCrossRef
22.
Verstegen RHJ, Phillips EJ, Juurlink DN. First-line therapy in drug reaction with eosinophilia and systemic symptoms (DReSS): thinking beyond corticosteroids. Front Med. 2023;10:1138464.CrossRef
23.
Newell BD, Moinfar M, Mancini AJ, Nopper AJ. Retrospective analysis of 32 pediatric patients with anticonvulsant hypersensitivity syndrome (ACHSS). Pediatr Dermatol. 2009;26(5):536–46.PubMedCrossRef
24.
Aihara Y, Ito S, Aihara M, Kobayashi Y, Yokota S. Different patterns of cytokines, ECP and immunoglobulin profiles at two adverse drug reactions in a patient. Pediatr Int. 2005;47(6):616–21.PubMedCrossRef
25.
Aouam K, Ben Romdhane F, Loussaief C, Salem R, Toumi A, Belhadjali H, et al. Hypersensitivity syndrome induced by anticonvulsants: possible cross-reactivity between carbamazepine and lamotrigine. J Clin Pharmacol. 2009;49(12):1488–91.PubMedCrossRef
26.
Troost RJ, Oranje AP, Lijnen RL, Benner R, Prens EP. Exfoliative dermatitis due to immunologically confirmed carbamazepine hypersensitivity. Pediatr Dermatol. 1996;13(4):316–20.PubMedCrossRef
27.
Chaabane A, Aouam K, Fredj NB, Boughattas NA. DRESS syndrome : étude de 11 cas et revue de la littérature. Therapies. 2010;65(6):543–50.CrossRef
28.
Ben Salem C, Slim R, Denguezli M, Nouira R, Hmouda H, Bouraoui K. A recurrent drug rash with eosinophilia and systemic symptoms. Pediatr Dermatol. 2007;24(6):666–8.PubMedCrossRef
29.
Semic-Jusufagic A, Ogese MO, Edwards C, Wilkinson M, Nissenbaum C, Lee T, et al. T-cell-mediated hypersensitivity to lumacaftor and ivacaftor in cystic fibrosis. Pediatr Allergy Immunol. 2022;33(6): e13815.PubMedCrossRef
30.
Mendiratta V, Bhushan P. Phenytoin-induced DRESS with cross-reactivity to carbamazepine in a 10-year-old Indian child. Clin Exp Dermatol. 2006;31(5):720–1.PubMedCrossRef
31.
Carroll MC, Yueng-Yue KA, Esterly NB, Drolet BA. Drug-induced hypersensitivity syndrome in pediatric patients. Pediatrics. 2001;108(2):485–92.PubMedCrossRef
32.
Mittal RR, Jain C, Walia RL, Chopra A. Drug-induced pseudolymphoma syndrome. Indian J Dermatol Venereol Leprol. 1995;61(2):94–5.PubMed
33.
Bessmertny O, Hatton RC, Gonzalez-Peralta RP. Antiepileptic hypersensitivity syndrome in children. Ann Pharmacother. 2001;35(5):533–8.PubMedCrossRef
34.
Chan AL. Pediatric fatality due to anticonvulsant hypersensitivity syndrome. Ann Pharmacother. 2003;37(6):918.PubMedCrossRef
35.
Chen CJ, Huang YC, Wang CY, Lin TY. Fatal anticonvulsant hypersensitivity syndrome in an infant. Eur J Pediatr. 2003;162(12):893–4.PubMedCrossRef
36.
Huang YL, Hong HS, Wang ZW, Kuo TT. Fatal sodium valproate-induced hypersensitivity syndrome with lichenoid dermatitis and fulminant hepatitis. J Am Acad Dermatol. 2003;49(2):316–9.PubMedCrossRef
37.
Mahe E, Bodemer C, Dupic L, Hubert P, Lacaille F, Goulet O, et al. Drug-induced hypersensitivity syndrome associated with primary Epstein-Barr virus and human herpesvirus 6 infections in a child intestinal transplant recipient. Transplantation. 2004;77(3):479–80.PubMedCrossRef
38.
Yu MK, Yu MC, Lee F. Association of DRESS syndrome with chylous ascites. Nephrol Dial Transplant. 2006;21(11):3301–3.PubMedCrossRef
39.
Eshki M, Allanore L, Musette P, Milpied B, Grange A, Guillaume JC, et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol. 2009;145(1):67–72.PubMedCrossRef
40.
Kitcharoensakkul M, Ree N, Bloomberg GR, Dehner LP, Heidingsfelder JA, White AJ, et al. Vancomycin-induced DRESS with evidence of T-cell activation in a 22-month-old patient. Ann Allergy Asthma Immunol. 2012;109(4):280–1.PubMedCrossRef
41.
Pereira CM, Vaz M, Kotha S, Santosh NH. Dapsone hypersensitivity syndrome with myocarditis. J Assoc Physicians India. 2014;62(8):728–31.PubMed
42.
Correa-de-Castro B, Paniago AM, Takita LC, Murback ND, Hans-Filho G. Drug reaction with eosinophilia and systemic symptoms: a clinicopathological study of six cases at a teaching hospital in midwestern Brazil. Int J Dermatol. 2016;55(3):328–34.PubMedCrossRef
43.
Goswami JN, Vaidya PC, Saini AG, De D, Radotra BD, Singhi PD. Drug reaction with eosinophilia and systemic symptoms in a child on multiple antiepileptics. Turk J Pediatr. 2017;59(2):197–9.PubMedCrossRef
44.
Rioualen S, Dufau J, Flatres C, Lavenant P, Misery L, Roue JM. DRESS complicated by hemophagocytic lymphohistiocytosis in an infant treated for congenital toxoplasmosis. Ann Dermatol Venereol. 2017;144(12):784–7.PubMedCrossRef
45.
Chua GT, Rosa Duque JS, Chong PCY, Lee PPW, Lau YL, Ho MHK. Paediatric case series of drug reaction with eosinophilia and systemic symptoms (DRESS): 12-year experience at a single referral centre in Hong Kong and the first reported use of infliximab. Eur Ann Allergy Clin Immunol. 2018;50(6):273–6.PubMedCrossRef
46.
Aljundi N, Utz Petry S, Moossavi M, Daveluy S. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms following nivolumab and ipilimumab in a pediatric patient with melanoma. Pediatr Dermatol. 2022;39(3):486–7.PubMedCrossRef
47.
Brown RJ, Rother KI, Artman H, Mercurio MG, Wang R, Looney RJ, et al. Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae. Arch Dermatol. 2009;145(1):63–6.PubMedPubMedCentralCrossRef
48.
Lan J, Lahoti A, Lew DB. A severe case of minocycline-induced DRESS resulting in liver transplantation and autoimmune sequelae. Ann Allergy Asthma Immunol. 2016;116(4):367–8.PubMedCrossRef
49.
Coughlin CC, Jen MV, Boos MD. Drug hypersensitivity syndrome with prolonged course complicated by parvovirus infection. Pediatr Dermatol. 2016;33(6):e364–5.PubMedCrossRef
50.
Han XD, Koh MJ, Wong SMY. Drug reaction with eosinophilia and systemic symptoms in a cohort of Asian children. Pediatr Dermatol. 2019;36(3):324–9.PubMedCrossRef
51.
Werbel T, Castrovinci P, Contestable J. Ethosuximide-induced drug reaction with eosinophilia and systemic symptoms with mediastinal lymphadenopathy. Pediatr Dermatol. 2019;36(4):e99–101.PubMedCrossRef
52.
Satake M, Kudo K, Masuda A, Onoyama S, Furuno K, Furue M. Drug-induced hypersensitivity syndrome by iv immunoglobulin administration for Kawasaki disease. J Dermatol. 2020;47(3):e74–5.PubMedCrossRef
53.
Morita C, Yanase T, Shiohara T, Aoyama Y. Aggressive treatment in paediatric or young patients with drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) is associated with future development of type III polyglandular autoimmune syndrome. BMJ Case Rep. 2018;2018:bcr-2018-225528.
54.
Tempark T, Tangthanapalakul A, Deekajorndech T, Chatproedprai S, Supornsilchai V, Wananukul S. Graves’ disease: an uncommon cause of late sequelae following DRESS (drug reaction with eosinophilia and systemic symptoms). Clin Exp Pediatr. 2022;65(12):602–4.PubMedPubMedCentralCrossRef
55.
Zhu B, Wu J, Chen G, Yang Y, Yi C. Fulminant type 1 diabetes mellitus caused by drug reaction with eosinophilia and systemic symptoms (DRESS): a case report and review of the literature. Front Endocrinol (Lausanne). 2019;10:474.PubMedPubMedCentralCrossRef
56.
Dibek Misirlioglu E, Guvenir H, Bahceci S, Haktanir Abul M, Can D, Usta Guc BE, et al. Severe cutaneous adverse drug reactions in pediatric patients: a multicenter study. J Allergy Clin Immunol Pract. 2017;5(3):757–63.PubMedCrossRef
57.
Huang YL, Hsieh MY, Hsiao PF, Sheen JM, Yu HR, Kuo HC, et al. Alopecia areata universalis after phenobarbital-induced anti-convulsant hypersensitivity syndrome. Immunol Invest. 2009;38(5):383–97.PubMedCrossRef
58.
Hollingsworth P, Paci K, Evans M, Miedema J, Morrell DS. Alopecia universalis after drug reaction with eosinophilia and systemic symptoms (Dress). Pediatr Dermatol. 2020;37(5):947–9.PubMedCrossRef
59.
60.
Alexander T, Iglesia E, Park Y, Duncan D, Peden D, Sheikh S, et al. Severe DRESS syndrome managed with therapeutic plasma exchange. Pediatrics. 2013;131(3):e945–9.PubMedCrossRef
61.
Martanto W, Pan JY. Severe DRESS syndrome secondary to sulfamethoxazole/trimethoprim complicated by hyperthyroidism, photosensitivity, anhidrosis, and juvenile idiopathic arthritis. Dermatol Sin. 2015;33(1):33–4.CrossRef
62.
Dahl AR, Knoebel EE, Lloyd RM. DRESS following FIRES: a clinical conundrum. Clin Pediatr (Phila). 2018;57(12):1479–82.PubMedCrossRef
63.
Song SM, Cho MS, Oh SH, Kim KM, Park YS, Kim DY, et al. Liver transplantation in a child with acute liver failure resulting from drug rash with eosinophilia and systemic symptoms syndrome. Korean J Pediatr. 2013;56(5):224–6.PubMedPubMedCentralCrossRef
64.
Garcia A, Yi NJ, Lee KB, Lee JM, Choi YR, Suh SW, et al. Fulminant hepatitis linked to dapsone hypersensitivity syndrome requiring urgent living donor liver transplantation: a case report. Pediatr Transplant. 2014;18(7):E240–5.PubMedCrossRef
65.
Álvarez-García L, López Amor L, Escudero AD. Liver transplantation in a patient with fulminant hepatitis by DRESS syndrome. Med Clín (Barc). 2021;156(7):363–4.PubMedCrossRef
66.
Erdem SB, Nacaroglu HT, Bag O, Karkiner CS, Korkmaz HA, Can D. DRESS syndrome associated with type 2 diabetes in a child. Cent Eur J Immunol. 2015;40(4):493–6.PubMedCrossRef
Metadaten
Titel
Management and Long-Term Outcomes of Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS) in Children: A Scoping Review
verfasst von
Nicole Cherepacha
Frances St George-Hyslop
Bindiya Chugani
Yousef Alabdeen
Luis F. Sanchez-Espino
Quenby Mahood
Cathryn Sibbald
Ruud H. J. Verstegen
Publikationsdatum
16.05.2024
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-024-00867-y

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise